Dr. Vogelzang Discusses Cabozantinib's Dose Size

Video

Dr. NJ Vogelzang from the Comprehensive Cancer Centers of Nevada Discusses Cabozantinib's Dose Size

Nicholas J. Vogelzang, MD, head of the Genitourinary Cancer Section at the Comprehensive Cancer Centers of Nevada discusses the cabozantinib (XL184) dose size concerns, the drug accumulation effect that occurs, and alternative dosing strategies.

Related Videos
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Zeynep Eroglu, MD
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD
Related Content
stock.adobe.com

Toripalimab NDA Under Review in Hong Kong for Nasopharyngeal Carcinoma

April 25th 2024
Article
OncLive On Air

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024
Podcast
Antonio Alcaraz, PhD, chairman, Department of Urology, University Hospital Clinic of Barcelona

Enzalutamide Receives Go Ahead From European Commission in nmHSPC

April 24th 2024
Article
Bradley J. Monk, MD, FACOG, FACS; Paolo Tarantino, MD

Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

January 11th 2024
Podcast
Subcutaneous Atezolizumab in Cancer: © vxnaghiyev - stock.adobe.com

Health Canada Green Lights Subcutaneous Atezolizumab for Lung, Breast, and Liver Cancer

April 23rd 2024
Article
Spencer Heaton, MD, MBA, of Lynx Dx

New Prostate Cancer Urine Test Produces Greater Diagnostic Accuracy vs Existing Tests in High-Grade Prostate Cancer

April 23rd 2024
Article